The Recall Desk

Category

Drug recalls

FDA recalls of prescription and over-the-counter drugs.

About drug recalls

FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.

The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.

If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.

4776–4800 of 5168

  • HighFDA (Drugs)·D-0119-2022·2021-11-17

    IC B Complex Injectable Recalled for Lack of Sterility Assurance

    Talon Compounding Pharmacy is recalling IC B Complex Injectable due to lack of assurance of sterility. The affected vial lot 09152021:12 was distributed across the United States, Washington, D.C., and Puerto Rico.

    Product
    IC B COMPLEX INJ INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
    Category
    Drug
    Distribution
    0 states
  • ModerateFDA (Food)·F-0156-2022·2021-11-17

    NOW Ginseng & Royal Jelly supplement may contain Metronidazole

    NOW Health Group Inc. is recalling NOW Ginseng & Royal Jelly 90 VCAPS and MMA Nutrition Ginselin 90 Veg Capsules because the products may contain Metronidazole, an undeclared pharmaceutical ingredient.

    Product
    NOW Ginseng & Royal Jelly 90 VCAPS UPC 733739040077 MMA Nutrition Ginselin 90 Veg Capsules UPC 733739440075
    Category
    Drug
    Distribution
    47 states
  • ModerateFDA (Drugs)·D-0227-2022·2021-11-17

    Ezetimibe and Simvastatin Tablets Recalled for Defective Excipient and Foreign Tablets

    Golden State Medical Supply Inc. is recalling specific lots of Ezetimibe and Simvastatin 10 mg/40 mg tablets because an excipient used in manufacturing failed to meet conductivity specifications, and some bottles were found to contain foreign tablets.

    Product
    EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
    Category
    Drug
    Distribution
    2 states
  • ModerateFDA (Drugs)·D-0228-2022·2021-11-17

    Ezetimibe and Simvastatin Tablets Recalled for Excipient Specification Failure

    Golden State Medical Supply Inc. is recalling Ezetimibe and Simvastatin 10 mg/80 mg tablets because the product was manufactured using an excipient that failed conductivity specifications.

    Product
    EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
    Category
    Drug
    Distribution
    2 states
  • ModerateFDA (Drugs)·D-0095-2022·2021-11-17

    Acetaminophen Oral Suspension Recalled Due to Contaminated Raw Ingredient

    Precision Dose Inc. is recalling Acetaminophen Oral Suspension (325 mg/10.15 mL) due to contaminated raw ingredient used in manufacturing. The recall affects 151,100 unit dose cups distributed nationwide for hospital use.

    Product
    ACETAMINOPHEN — ACETAMINOPHEN (ACETAMINOPHEN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0230-2022·2021-11-17

    Tadalafil Tablets Recalled for Incorrect Product Formulation

    Sun Pharmaceutical Industries is recalling Tadalafil 5 mg tablets (Lot # DNC1127A) because an incorrect grade of Crospovidone was used during manufacturing. The product was distributed to one distributor who may have further distributed it nationwide.

    Product
    TADALAFIL — TADALAFIL (TADALAFIL)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0231-2022·2021-11-17

    Tadalafil Tablets Recalled Due to Incorrect Product Formulation

    Sun Pharmaceutical is recalling Tadalafil Tablets USP 20 mg due to use of an incorrect grade of Crospovidone during manufacturing. The recall affects 36,786 bottles distributed to one distributor.

    Product
    TADALAFIL — TADALAFIL (TADALAFIL)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0094-2022·2021-11-17

    Acetaminophen Oral Suspension Recalled Due to Contaminated Raw Ingredient

    Precision Dose Inc. is recalling 166,920 unit dose cups of Acetaminophen Oral Suspension 160 mg/5 mL (Lot 503670) distributed nationwide due to cGMP deviations involving contaminated raw ingredient used in manufacturing.

    Product
    ACETAMINOPHEN — ACETAMINOPHEN (ACETAMINOPHEN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0213-2022·2021-11-17

    TRI-MIX PAPAVERINE Injectable Recalled for Lack of Sterility Assurance

    Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling TRI-MIX PAPAVERINE 30/PHENTOLAMINE 2/PGE-1 40 INJ injectable vials due to lack of assurance of sterility.

    Product
    TRI-MIX PAPAVERINE 30/PHENTOLAMINE 2/PGE-1 40 INJ INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
    Category
    Drug
    Distribution
    0 states
  • LowFDA (Drugs)·D-0096-2022·2021-11-17

    Cetirizine Hydrochloride 10 mg Tablets Labeling Error Recall

    A-S Medication Solutions LLC is recalling Cetirizine hydrochloride 10 mg tablets due to a labeling error: bottles were labeled as 90-count when they actually contain 30 tablets.

    Product
    CETIRIZINE — CETIRIZINE (CETIRIZINE HYDROCHLORIDE)
    Category
    Drug
    Distribution
    4 states
  • SevereFDA (Drugs)·D-0092-2022·2021-11-10

    Methocarbamol Tablets Mislabeled with Incorrect Strength

    Bryant Ranch Prepack is recalling Methocarbamol 500mg tablets nationwide because the bottles are mislabeled—they actually contain 750mg tablets. The affected lot was distributed in 30-, 60-, and 90-count bottles.

    Product
    Methocarbamol 500mg Tablet, packaged in a) #30 count (NDC 7133517952), b) #60 count (NDC 7133517954), and c) #90 count (NDC 7133517957) bottles, Rx only, Prinston Laboratories, Packaged by Bryant Ranch Prepack Burbank, CA 91504
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0093-2022·2021-11-10

    Cubicin daptomycin injection recalled for glass particle contamination

    Merck Sharp & Dohme Corp. is recalling Cubicin (daptomycin for injection) 500 mg vials due to the presence of glass particles. The recall affects a single lot distributed nationwide.

    Product
    Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0089-2022·2021-11-10

    Irbesartan and Hydrochlorothiazide Tablets Recalled for Impurity Contamination

    Lupin Pharmaceuticals is recalling Irbesartan and Hydrochlorothiazide Tablets 150/12.5 mg due to detection of the impurity N-nitrosoirbesartan in the active pharmaceutical ingredient, which resulted from CGMP deviations.

    Product
    Irbesartan and Hydrochlorothiazide Tablets USP, 150/12.5 mg a) 30 count (NDC 68180-413-06) and b) 90 count (NDC 68180-413-09) bottles, Rx only
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0087-2022·2021-11-10

    Irbesartan Tablets Recalled for Impurity in Active Ingredient

    Lupin Pharmaceuticals is recalling Irbesartan tablets due to the detection of N-nitrosoirbesartan impurity in the active pharmaceutical ingredient. The recall affects 30-count and 90-count bottles distributed nationwide.

    Product
    IRBESARTAN — IRBESARTAN (IRBESARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0090-2022·2021-11-10

    Lupin Pharmaceuticals Irbesartan/Hydrochlorothiazide Tablets Recalled for Impurity

    Lupin Pharmaceuticals is recalling Irbesartan and Hydrochlorothiazide Tablets USP (300/12.5 mg) in 30-count and 90-count bottles due to detection of the impurity N-nitrosoirbesartan in the active pharmaceutical ingredient.

    Product
    Irbesartan and Hydrochlorothiazide Tablets USP, 300/12.5 mg a) 30 count (NDC 68180-414-06) and b) 90 count (NDC 68180-414-09) bottles, Rx only
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-0086-2022·2021-11-10

    Lupin Irbesartan Tablets Recalled for Impurity Contamination

    Lupin Pharmaceuticals is recalling Irbesartan 75 mg tablets due to detection of the impurity N-nitrosoirbesartan in the active pharmaceutical ingredient. The recall affects 51,144 bottles distributed nationwide.

    Product
    IRBESARTAN — IRBESARTAN (IRBESARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0083-2022·2021-11-10

    Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications

    Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin Tablets (10 mg/80 mg) because the product was manufactured using an excipient that failed to meet conductivity specifications.

    Product
    EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0081-2022·2021-11-10

    Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Excipient Specification Failure

    Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin 10 mg/10 mg tablets nationwide because the product was manufactured using an excipient that failed to meet conductivity specifications.

    Product
    EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0088-2022·2021-11-10

    Irbesartan 300 mg tablets recalled for impurity in active ingredient

    Lupin Pharmaceuticals is recalling Irbesartan 300 mg tablets due to the detection of N-nitrosoirbesartan impurity in the active pharmaceutical ingredient. The recall affects approximately 119,544 bottles distributed nationally.

    Product
    IRBESARTAN — IRBESARTAN (IRBESARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0084-2022·2021-11-10

    Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications

    Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin 10 mg/40 mg tablets because an excipient used in manufacturing failed conductivity specifications. The recall affects 11,590 bottles of 30-count and 3,585 bottles of 90-count packages distributed nationwide.

    Product
    EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0082-2022·2021-11-10

    Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications

    Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin Tablets (10 mg/20 mg) nationwide because the product was manufactured using an excipient that failed conductivity specifications.

    Product
    EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0085-2022·2021-11-10

    Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications

    Dr. Reddy's Laboratories is recalling 696 bottles of Ezetimibe and Simvastatin Tablets (10 mg/40 mg) distributed nationwide due to failed excipient specifications and the presence of foreign tablets in bottles.

    Product
    EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0066-2022·2021-11-03

    Progesterone 100mg/ml Oil Injection Recall: Sterility Assurance Defect

    Red Mountain Compounding Pharmacy is recalling Progesterone 100mg/ml MDV Oil Injection due to lack of assurance of sterility following FDA inspection. About 494 patients in seven states received prescriptions for this affected product.

    Product
    PROGESTERONE 100MG/ML MDV OIL INJECTION, Rx only, Red Mountain Compounding Rx
    Category
    Drug
    Distribution
    7 states
  • SevereFDA (Drugs)·D-0030-2022·2021-11-03

    Levocarnitine 100mg/mL Solution Recall Due to Sterility Assurance

    Red Mountain Compounding Pharmacy is recalling Levocarnitine 100mg/mL solution for injection because FDA inspection found concerns about the product's sterility assurance. The product was distributed to patients in seven states.

    Product
    LEVOCARNITINE 100MG/ML MDV SOLN, Rx only, Red Mountain Compounding Rx
    Category
    Drug
    Distribution
    7 states

Looking for a different category? Browse all recalls.